Trademark: 90867023
Word
COSMX
Status
Pending
Status Code
807
Status Date
Tuesday, February 6, 2024
Serial Number
90867023
Mark Type
4000
Filing Date
Thursday, August 5, 2021
Published for Opposition
Tuesday, May 30, 2023

Trademark Owner History
NanoString Technologies, Inc. - Owner At Publication

Classifications
9 Automated apparatus in the nature of automated laboratory equipment, namely, computer and networking hardware, and computer systems comprised of computer hardware and downloadable computer software for detection and analysis of biomolecules for scientific use; automated apparatus in the nature of automated laboratory equipment, namely, computer and networking hardware and computer systems comprised of computer hardware and downloadable computer software for scientific research, namely, for detecting, collecting and processing optical signals and images, into data for use in the analysis of biomolecules in connection with scientific and medical research; automated apparatus in the nature of automated laboratory equipment in the nature of digital imagers, namely, apparatus for recording, transmission and reproduction of images, digital signage display panels, microscopes, robotics in the nature of laboratory robots, fluidic stations in the nature of automatic fluid-composition control machines and instruments, and computer systems comprised of computer hardware and downloadable computer software for staining and visualization of tissue and cell based samples for diagnostic and scientific use; automated apparatus in the nature of automated laboratory equipment in the nature of digital imagers, namely, apparatus for recording, transmission and reproduction of images, digital signage display panels, microscopes, robotics in the nature of laboratory robots and computer systems comprised of computer hardware and downloadable computer software for digitizing images of biological tissue for use in connection with pathology; automated apparatus in the nature of automated laboratory equipment in the nature of digital imagers, namely, apparatus for recording, transmission and reproduction of images, digital signage display panels, microscopes, robotics in the nature of laboratory robots, and computer systems comprised of computer hardware and downloadable computer software for capturing digital images of microscope slides of biological tissue, storage of digitized microscope slide images in a data storage area, and display of digitized microscope slide images; automated apparatus in the nature of automated laboratory equipment in the nature of digital imagers, namely, apparatus for recording, transmission and reproduction of images, digital signage display panels, microscopes, robotics in the nature of laboratory robots, fluidic stations in the nature of automatic fluid-composition control machines and instruments, and computer systems comprised of computer hardware and downloadable computer software for detection and analysis of, pathology, gene expression, RNA transcription, RNA translation and nucleic acid sequencing; computer hardware and downloadable computer software to enable pathologists to diagnose disease; computer hardware and downloadable computer software for the electronic scanning of clinical pathology slides; computer hardware and downloadable computer software for pathologists to render and report diagnoses and results of scientific research; computer hardware and downloadable computer software for scientific and research uses in the fields of pathology, immunohistochemistry, in situhybridization, proteomics, RNA transcription and microRNA expression profiling and nucleic acid sequencing; computer hardware and downloadable computer software for digitizing, processing and storing images of biological tissues and cells; computer hardware and downloadable computer software for analyzing the results of tissues and cell based samples obtained through operation of tissue and cell sample staining and visualization apparatus; computer hardware and downloadable computer software for identifying and diagnosing cancer and other diseases and processing digital images; computer hardware and downloadable computer software for viewing, analyzing, managing, reporting, and archiving digital images; laboratory equipment for sample preparation, mixing, hybridization, incubation, washing, location and imaging, namely, robotic equipment, fluid mixers, pumps, valves, and containers, reagent holders, sample containers and microfluidic devices, optical devices, scanning microscopes, fluorescent microscopes, digital micromirror devices, electromagnetic sensors and replacement parts therefor in the fields of scientific research; downloadable computer application software for computer systems, namely, software and data files, namely, csv, TIF, png, JPEG, and fth files to acquire, analyze, manage and report biological information
5 Diagnostic reagents, namely, assays for medical and veterinary use in the fields of pathology, immunohistochemistry, in situhybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; diagnostic reagents for medical and veterinary use in the fields of cancer, neurology and infectious disease; diagnostic reagent kits comprising primarily of diagnostic reagents for medical and veterinary use in the fields of cancer, neurology and infectious disease; chemical reagents for medical use; reagents for medical and veterinary use containing antibodies and nucleic acids; diagnostic test kits for medical use comprising primarily of reagents, slides, solid matrix materials, microfluidic devices sold as a unit with instructional manuals therefor; medical and veterinary diagnostic kits comprising primarily of medical and veterinary diagnostic reagents for use in detecting the presence of analytes in samples and identifying sample type, and equipment, namely, medical diagnostic immuno-assays for screening samples detecting the presence of analytes in samples and identifying sample type, sold as a unit with instructional manuals; diagnostic preparations in the nature of antibodies, for medical and veterinary purposes; reagents and diagnostic reagents for medical and veterinary purposes; diagnostic preparations in the nature of in situ hybridization probes, for medical and veterinary purposes; medical and veterinary diagnostic reagents for pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; multiparameter quantitative detection and analysis products, namely, reagents and assays for medical diagnostics for a variety of uses in health care, namely, pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; medical diagnostic reagents and assays for testing of body fluids and tissue; diagnostic reagent kits consisting primarily of medical and veterinary diagnostic reagents and assays for testing of body fluids and tissue; reagents in the form of cell markers and molecule markers including antibodies and nucleic acids for medical and veterinary purposes; medical diagnostic reagents for use in the fields of pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; medical diagnostic reagents for use relating to molecular identification and digital quantification; medical diagnostic reagents containing antibodies and nucleic acids; medical diagnostic reagents for use in the fields of cancer, neurology and infectious disease; medical diagnostic reagents for immuno-histochemistry detection and in situhybridization detection
1 Reagents, namely, assays for scientific research and non-medical and non-veterinary diagnostic use in the fields of pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; diagnostic reagents for scientific and research use in the fields of cancer, neurology and infectious disease; reagents for scientific research and non-medical and non-veterinary diagnostic use relating to molecular identification and digital quantification; reagents for scientific research and non-medical and non-veterinary diagnostic use containing antibodies and nucleic acids; reagent kits comprising primarily reagents for scientific research and non-medical and non-veterinary diagnostic use in the fields of cancer, neurology and infectious disease; reagents for immunohistochemistry detection and in situhybridization detection for scientific research and non-medical and non-veterinary diagnostic use; chemical test kits for scientific research and non-medical and non-veterinary diagnostic use comprising reagents, slides, solid matrix materials, microfluidic devices and support documentation, namely, instructional manuals, therefor; chemical test kits comprising reagents for scientific research and non-medical and non-veterinary diagnostic use relating to molecular identification and digital quantification; reagents for in vitro use in clinical chemistry and molecular biology; reagents for clinical and medical laboratory use, namely, reagents for pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling, nucleic acid sequencing, and clinical, oncology, neurology, and infectious disease diagnostics; multiparameter quantitative detection and analysis products and technology for research and diagnostics for a variety of uses in the health care and other life science sectors, namely, reagents for scientific or medical research use, diagnostic preparations and reagents for scientific and research uses, namely, pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; chemical test kits, consisting of chemical preparations for scientific purposes, in particular for the detection, diagnosis, progress monitoring and progress prediction of diseases, including inflammations, infections, disorders of the central nervous systems, cardiovascular, neurological, endocrine, autoimmune and genetic disorders and cancers
10 Clinical and medical diagnostic instruments, namely, spatial molecular imagers, namely, devices for the detection, visualization and analysis of biological molecules at cellular and subcellular resolution; clinical and medical diagnostic instruments, namely, histopathology instruments and nucleic acid sequencers; clinical and medical diagnostic instruments for analysis of tissue and cell based samples, all for medical purposes; clinical and medical diagnostic instruments for performing immunohistochemistry and in situ-hybridization staining reactions, histological and pathological staining and image processing and analysis; histopathology instruments for clinical purposes; clinical and medical diagnostic instruments for immunohistochemistry and in situ-hybridization analyses; clinical and medical diagnostic instruments for the electronic scanning of clinical pathology slides, processing and storing images of biological tissues and cells and digitizing, processing and storing images of biological tissues and cells
42 research and product development services for others in the field of biotechnology; medical and scientific research services for others in the fields of pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; medical and scientific research in the field of cancer treatment and diagnosis; medical and scientific research services for others in the field of infectious disease; medical and scientific research services for others in the field of neurology; medical and scientific research services for others, namely, research and design in the field of testing, analyzing and examining biological samples, medical samples, and cell samples; providing laboratory research services for others in the field of gene expression and genetic data mining; research and development services for others for acquiring, analyzing, and managing biological and genetic information in the fields of forensics, medicine, genetics, and environment; Scientific research, design, and development services, for others, of single-cell imaging products for acquiring, analyzing, and managing diagnostic reagents, compounds and devices, measuring apparatus for use in product research and development, separation processes, data acquisition, analysis, management and reporting of biological information in the fields of healthcare, pathology, immunohistochemistry, in situhybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing

Trademark Events
Apr 5, 2024
Teas Response To Office Action Received
Feb 6, 2024
Notification Of Non-Final Action E-Mailed
Feb 6, 2024
Non-Final Action E-Mailed
Feb 6, 2024
Su - Non-Final Action - Written
Jan 6, 2024
Statement Of Use Processing Complete
Dec 14, 2023
Use Amendment Filed
Jan 5, 2024
Case Assigned To Intent To Use Paralegal
Dec 14, 2023
Teas Statement Of Use Received
Jul 25, 2023
Noa E-Mailed - Sou Required From Applicant
May 30, 2023
Official Gazette Publication Confirmation E-Mailed
May 30, 2023
Published For Opposition
May 10, 2023
Notification Of Notice Of Publication E-Mailed
Apr 25, 2023
Approved For Pub - Principal Register
Apr 13, 2023
Examiner's Amendment Entered
Apr 13, 2023
Notification Of Examiners Amendment E-Mailed
Apr 13, 2023
Examiners Amendment E-Mailed
Apr 13, 2023
Examiners Amendment -Written
Feb 18, 2023
Teas/Email Correspondence Entered
Feb 17, 2023
Correspondence Received In Law Office
Feb 17, 2023
Teas Response To Office Action Received
Feb 13, 2023
Notification Of Non-Final Action E-Mailed
Feb 13, 2023
Non-Final Action E-Mailed
Feb 13, 2023
Non-Final Action Written
Oct 25, 2022
Teas/Email Correspondence Entered
Oct 24, 2022
Correspondence Received In Law Office
Oct 24, 2022
Teas Response To Office Action Received
Jul 28, 2022
Notification Of Non-Final Action E-Mailed
Jul 28, 2022
Non-Final Action E-Mailed
Jul 28, 2022
Non-Final Action Written
May 12, 2022
Examiner's Amendment Entered
May 12, 2022
Notification Of Examiners Amendment E-Mailed
May 12, 2022
Examiners Amendment E-Mailed
May 12, 2022
Examiners Amendment -Written
May 4, 2022
Assigned To Examiner
Sep 30, 2021
New Application Office Supplied Data Entered
Aug 9, 2021
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24